|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To better understand the role of NAT2 genetic polymorphism in ABP- and AF-induced mutagenesis and DNA damage, nucleotide excision repair-deficient (UV5) Chinese hamster ovary (CHO) cells were stably transfected with human CYP1A2 and either NAT2*4 (rapid acetylator) or NAT2*5B (slow acetylator) alleles.
|
31490564 |
2020 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the genotypic distribution of variants of slow-acetylator genotypes (NAT2*6/7, NAT2*5/7, and NAT2*5/6) was also not significantly different in ATDIH.
|
31245212 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The slow acetylator status of N-acetyl transferase 2 (NAT2) is a well-established risk factor for ATDH.
|
31066138 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> NAT2 slow acetylator was significantly associated with AT-DILI risk (p = 2.7 × 10<sup>-7</sup>; odds ratio [95% CI] = 3.64 [2.21-6.00]).
|
31699005 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
|
29781872 |
2018 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subjects with rapid NAT2 genotype showed an apparent V<sub>max</sub> of 42.1 ± 2.4; intermediate NAT2 genotypes an apparent V<sub>max</sub> of 22.6 ± 2.2; and slow acetylator NAT2 genotypes an apparent V<sub>max</sub> of 19.9 ± 1.7 nM acetyl-isoniazid/24 h/million cells.
|
30149019 |
2018 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Slow acetylator phenotype in the rabbit results from deletion of the N-acetyltransferase 2 (NAT2) gene.
|
28536864 |
2017 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, combined analysis of the NAT2/CYP2E1 gene polymorphisms showed that patients with both DraI C/D and slow acetylator have an increased risk of IIH compared with other combined NAT2/CYP2E1 genotype profiles (OR: 8.41, P=0.01, 95% CI: 1.54-45.76).
|
27089936 |
2017 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results suggest that the NAT2 slow acetylator, in particular, the NAT2 slow acetylator combined with smoking, are associated with an increased bladder cancer risk.
|
26585839 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to identify polymorphisms of genes encoding metabolic enzymes NAT2 and GSTM1 in tuberculosis patients in Latvia and to estimate the frequency of NAT2 slow acetylator and GSTM1 null genotypes.
|
27236516 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We inferred the NAT1 rapid and slow acetylator and the NAT2 rapid, intermediate or slow acetylator phenotype, based on published functional data on the respective genotypes.
|
25689677 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the NAT2 polymorphism was believed to be associated with increased risk of CHD, with the NAT2 slow acetylator genotype serving as a risk factor for severe CHD in a Chinese population.
|
26985933 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
|
27725049 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, there was a synergic effect of NAT2 slow acetylator and well-done meat intake to the development of GNA (odds ratio = 3.83; 95% confidence interval, 1.68-8.76, p = 0.001).
|
26617241 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The presence of NAT2 slow acetylator genotype, and CYP1A2, GSTA1, and GSTM3 variants were associated with an average 3-5 fold increased risk.
|
25719551 |
2015 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, NAT2 gene polymorphism(s) with slow acetylator phenotype is generally associated with the risk of development of ALL in children.
|
25804798 |
2015 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, the diameters of the portal vein and splenic vein as well as spleen thickness in NAT2 rapid acetylator genotype were obviously bigger than that in the NAT2 slow acetylator genotype.
|
25574899 |
2015 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the ADRs emerged earlier in the AS cases carrying both NAT1 and NAT2 slow acetylator genotypes.
|
25413361 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study indicates that patients with slow-acetylator genotypes (NAT2 5/7, 6/7) and GSTM1 allele of GST enzyme were at higher risk of ATT-induced hepatotoxicity.
|
24188272 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type), homozygous null GSTM1 genotype and MnSOD mutant C allele.
|
24593909 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow acetylator genotype appears to be a significant risk factor for moderate and severe drug- induced liver injury.
|
24888881 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report here a statistically significant correlation between the NAT2*5C/NAT2*6A slow acetylator genotype and the risk for developing prostate cancer (OR 2.91; 95 % CI 1.43-5.94; p = 0.003) when compared with the rapid phenotype.
|
24816842 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risks of hepatic injury were higher after anti-tuberculosis therapy in patients carrying the NAT2 slow acetylator, CYP2E1 -1259G>C, -1019C>T wild-type, and GSTM1 null genotype.
|
25501156 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present meta-analysis indicates that the CYP2E1 c1/c1 genotype may be a risk factor for ATDH, and the concomitant presence of the slow acetylator NAT2 genotype may further increase this risk.
|
24607341 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, we found significant association between slow acetylator genotype of NAT2 and ATDH (OR = 3.10, 95% CI: 2.47-3.88, P < 10(-5)).
|
23277397 |
2013 |